Latest Treatments for Ulcerative Colitis: 2025 Guide

Ulcerative colitis (UC) care is moving fast—new medicines can control flares, heal the bowel, and reduce steroid use better than ever.

This guide breaks down UC symptoms, when to seek care, how to choose the right therapy, and the latest treatments—plus which option is most effective today.

Symptoms of Ulcerative Colitis

UC is a chronic inflammation of the colon that typically causes bloody diarrhea, urgent bowel movements, abdominal cramping, fatigue, and weight loss. You might also notice mucus in the stool, low appetite, or anemia from blood loss. Learn more about common signs from trusted sources like the Mayo Clinic and the Crohn’s & Colitis Foundation.

Symptoms tend to wax and wane—with flares and periods of remission. Extraintestinal problems can occur too, including joint pain, skin rashes, eye inflammation, and liver disease. These may parallel gut activity or flare independently. If you notice new eye pain, severe joint swelling, or painful skin nodules, tell your clinician promptly.

These symptoms can influence which therapy is best for you.

Call your doctor urgently for red flags such as high fever, severe abdominal pain, persistent vomiting, signs of dehydration, or heavy rectal bleeding—these can reflect complications that sometimes require hospital care.

When to see a doctor and consider new treatments

Don’t wait out repeated flares. Seek care if you have ongoing blood in stool, increasing urgency, nighttime symptoms, or if flares are impacting work, school, or daily life. Early evaluation helps prevent steroid dependence and complications.

Urgent help now: severe bleeding, fever >101.5°F (38.6°C), intense abdominal pain, dehydration, or fainting.
Schedule a prompt GI visit: two or more flares in a year, need for steroids, partial response to current meds, or rising biomarkers (CRP, fecal calprotectin).
Reassess your plan: if you’re missing activities, losing weight, or waking at night to stool, it’s time to consider advanced therapies.

Modern UC care follows a treat-to-target approach—aiming for symptom control and objective healing (normalizing biomarkers and mucosal healing on colonoscopy). This strategy, endorsed by international groups (see STRIDE-II), is linked with fewer hospitalizations and surgeries.

How to choose the right treatment

Set clear goals

Work with your gastroenterologist to target steroid-free remission, improved quality of life, normalized inflammation labs (CRP, fecal calprotectin), and endoscopic healing. The AGA clinical guidance can help frame these goals.

Match therapy to your profile

Disease severity and extent: extensive or severe disease often requires advanced therapies.
Prior drug exposure: some options work especially well if you’ve failed biologics; others are ideal first-line advanced therapies.
Speed needed: if symptoms are severe, faster-acting agents can help quickly.
Comorbidities and risks: infection history, heart issues, blood clots, liver disease, and pregnancy plans guide choice.
Convenience and cost: oral vs infusion/injection, insurance coverage, and patient assistance programs matter.

Partner closely with your care team

Update vaccinations before immunosuppression (flu, COVID-19, shingles as appropriate).
Baseline screenings: TB and hepatitis B/C for many advanced therapies.
Track progress with symptoms plus labs (calprotectin, CRP) and periodic colonoscopy.
Address nutrition, iron deficiency, bone health, and mental well-being.

The latest treatments for ulcerative colitis (2023–2025)

Beyond long-standing options (e.g., anti-TNF agents and vedolizumab), several newer therapies expand choices for moderate to severe UC. Below are five widely used, recently approved, or newly prominent therapies—what they are, who they suit, and key safety notes. For full prescribing details, review the FDA labels linked below with your clinician.

1) Upadacitinib (Rinvoq) — targeted JAK1 inhibitor, oral

What it is: A once-daily pill that selectively blocks JAK1 to dampen inflammatory signaling. Trials show rapid symptom relief and high remission rates, even in patients who previously failed biologics. See the FDA label for specifics (Rinvoq label).

Best fit: Patients needing fast induction of remission or those who have tried and failed other biologics.

Watch-outs: Risks include infections, shingles, lab changes (lipids, liver enzymes), and rare blood clots; requires screenings and labs per the label.

2) Etrasimod (Velsipity) — S1P receptor modulator, oral

What it is: A once-daily pill that keeps certain white blood cells from trafficking to the gut, reducing inflammation. Induction and maintenance trials demonstrated meaningful remission and endoscopic improvement. Details: Velsipity label.

Best fit: Patients preferring an oral option with a favorable long-term safety profile in studies.

Watch-outs: Can affect heart rate and conduction (particularly at start), liver enzymes, and infection risk; requires baseline review of cardiac history and selected monitoring.

3) Ozanimod (Zeposia) — S1P receptor modulator, oral

What it is: Another S1P modulator with established efficacy for UC and a dose-titration start to limit heart-rate effects. Label: Zeposia label.

Best fit: Patients wanting a convenient oral therapy and steady maintenance option.

Watch-outs: Similar to etrasimod—review cardiac history, drug interactions, liver tests, and infection risks.

4) Mirikizumab (Omvoh) — IL‑23 p19 monoclonal antibody

What it is: Targets the IL‑23 pathway central to UC inflammation. Given by IV induction then subcutaneous maintenance; trials showed significant endoscopic and histologic healing. Label: Omvoh label.

Best fit: Patients seeking a biologic with strong mucosal healing data and convenient at-home maintenance injections.

Watch-outs: Screen for TB; monitor for infections and rare hypersensitivity reactions.

5) Risankizumab (Skyrizi) — IL‑23 p19 monoclonal antibody

What it is: An IL‑23 inhibitor recently approved for UC, with robust induction and maintenance data and convenient subcutaneous dosing after induction. See manufacturer announcement for details (Skyrizi UC approval).

Best fit: Patients who prefer biologic therapy with a favorable side-effect profile and strong endoscopic outcomes in trials.

Watch-outs: TB screening and infection monitoring recommended; discuss vaccination timing with your clinician.

So, which option is most effective?

There’s no single winner for everyone, but across modern studies and guideline assessments, upadacitinib often ranks among the highest for induction of clinical remission—especially in patients who have previously used or failed biologics. IL‑23 inhibitors (mirikizumab, risankizumab) and S1P modulators (etrasimod, ozanimod) are strong options with favorable maintenance results and safety profiles. Your best choice depends on speed needed, prior drug exposure, safety preferences, and comorbidities; review the AGA guidance and trial data with your GI team.

Practical next steps

Document symptoms: stool frequency, urgency, blood, pain, nighttime symptoms; track daily for 1–2 weeks.
Ask about targets: what’s the plan to reach steroid-free remission and mucosal healing? How will success be measured?
Review options side-by-side: onset speed, route (oral vs injection/infusion), lab monitoring, pregnancy considerations, and infection risks.
Plan safety: vaccinations, TB/hepatitis screening, shingles vaccine if eligible, and lab schedule.
Check coverage: confirm prior authorization steps; ask about copay cards or foundations like the Crohn’s & Colitis Foundation for support resources.
Lifestyle add‑ons: iron and vitamin D repletion, evidence‑based diet guidance (e.g., limiting alcohol during flares), and stress‑reduction practices.

Quick FAQ

Can diet replace medication? Not for moderate to severe UC. Diet can reduce symptoms, but medications are usually required to control inflammation and prevent complications.
What if I feel better but labs are high? Silent inflammation can persist—stick with treat‑to‑target and recheck calprotectin/CRP and mucosal healing as advised.
When is surgery considered? For refractory disease, dysplasia/cancer, or complications. Modern therapy aims to prevent this, but timely surgical consults remain important.

Bottom line: New UC therapies give you real options. With clear targets, close monitoring, and a treatment tailored to your health profile, long‑term remission is an achievable goal.